10 recruiting, 8 active not recruiting, 5 completed, 5 unknown. 12 Phase 2, 8 Phase 1, 4 Not applicable, 3 Phase 3.
Follow HPV-Related Carcinoma: new trials by email Literature Review of HPV-Related Carcinoma trials Research Report on HPV-Related Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer HPV ctDNA Response based radiation, Chemotherapy, Retifanlimab - Anal Cancer, HPV-Related Carcinoma | Phase 2 | Recruiting | Jennifer Dorth | 33 | 2026-06-19 | 2026-08-14 |
| PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer PRGN-2009 plus Pembrolizumab - Cervical Cancer, HPV-Related Carcinoma | Phase 2 | Recruiting | Precigen, Inc | 24 | 2025-11-11 | 2026-04-23 |
| E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers E7 TCR-T cells, Aldesleukin - HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma | Phase 1 / Phase 2 | Recruiting | Christian Hinrichs | 15 | 2025-08-11 | 2026-10-28 |
| Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes ctDNA test, Pembrolizumab - HPV-Related Carcinoma, Uterine Cervical Cancer | Phase 2 | Recruiting | Instituto do Cancer do Estado de São Paulo | 150 | 2025-03-14 | 2025-12-24 |
| To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years Medium dose for 15-HPV vaccine, High dose for 15-HPV vaccine, Placebo - HPV Infection, HPV-Related Carcinoma | Phase 2 | Recruiting | Shanghai Bovax Biotechnology Co., Ltd. | 330 | 2025-01-15 | 2025-12-17 |
| A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years Placebo, 15-valent recombinant human papillomavirus vaccine (Hansenulapolymorpha) - HPV Infection, HPV-Related Carcinoma | Phase 1 | Unknown | Shanghai Bovax Biotechnology Co., Ltd. | 72 | 2024-08-03 | 2025-01-06 |
| A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha), Placebo - Genital Wart, Penile Cancer | Phase 3 | Active not recruiting | Shanghai Bovax Biotechnology Co., Ltd. | 9000 | 2024-07-11 | 2024-12-12 |
| IBRX-042 In Participants With HPV-Associated Tumors IBRX-042 - HPV-Related Carcinoma | Phase 1 | Active not recruiting | ImmunityBio, Inc. | 12 | 2024-06-14 | 2026-08-31 |
| A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors TSC-204-A0201, TSC-204-C0702, TSC-200-A0201 - Head and Neck Cancer, Cervical Cancer | Phase 1 | Active not recruiting | TScan Therapeutics, Inc. | 840 | 2024-05-06 | 2025-11-17 |
| Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC) combined HPV 16 DNA and host gene methylation oral biomarker panel - Oropharyngeal Cancer, HPV-Related Carcinoma | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 400 | 2024-01-22 | 2026-09-23 | |
| Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer Radiation, Platinum based chemotherapy - Oropharynx Cancer, HPV-Related Carcinoma | Phase 2 | Active not recruiting | University of Michigan Rogel Cancer Center | 19 | 2023-12-20 | 2026-05-18 |
| Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection pNGVL4a-Sig/E7(detox)/HSP70 plasmid DNA; TA-HPV vaccinia virus - HPV 16 Infection, HPV-Related Carcinoma | Phase 1 | Enrolling by invitation | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 24 | 2023-10-18 | 2026-03-06 |
| A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell）, placebo - HPV InfectioN, HPV-Related Carcinoma | Phase 3 | Active not recruiting | Sinocelltech Ltd. | 18000 | 2023-08-13 | 2023-09-18 |
| Radiosensitivity of HPV-related Tumors: Towards a Genomic Approach Radiation therapy as curative treatment - HPV-Related Carcinoma | Unknown | European Institute of Oncology | 100 | 2023-04-14 | 2024-03-20 | |
| A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC) NavDx - Oropharyngeal Cancer, HPV-Related Carcinoma | Active not recruiting | Memorial Sloan Kettering Cancer Center | 9 | 2023-03-31 | 2026-09-23 | |
| E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers E7 TCR-T cells, Aldesleukin - Cervical Cancer, Throat Cancer | Phase 2 | Recruiting | Christian Hinrichs | 20 | 2023-03-07 | 2026-10-28 |
| Determining the Frequency of Occurrence and Defining the Most Appropriate Screening Test for Anal Intraepithelial Neoplasia (AIN) in Patients With Human Papillomavirus (HPV) Related Gynecological Diseases. hrHPV test and cytology - HPV-Related Carcinoma, HPV Infection | Not applicable | Recruiting | PCK Marine Hospital in Gdynia | 248 | 2023-01-13 | 2025-07-23 |
| A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 18-45 Years 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha), placebo - HPV InfectioN, HPV-Related Carcinoma | Phase 3 | Active not recruiting | National Vaccine and Serum Institute, China | 13500 | 2022-06-04 | 2026-10-28 |
| A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC) HPV ctDNA Assay, MRI Studies, EORTC QLQ H&N 35 and C30 - HPV, Oropharynx Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2022-03-24 | 2026-04-13 |
| HPV Vaccine Effectiveness Study in Rwandan Women Living With HIV Blood collection, Oral, cervicovaginal and anal specimen collection, Anoscopy & Biopsy of Acetowhite Lesions - Cervical Cancer, Human Papilloma Virus | Completed | Montefiore Medical Center | 3127 | 2021-11-03 | 2025-10-16 |
Showing 20 of 31. Sign in to see all of them.
Uterine Cervical Neoplasms (8) · Oropharyngeal Neoplasms (7) · Anus Neoplasms (6) · Papillomavirus Infections (5) · Head and Neck Neoplasms (4) · Neoplasm Metastasis (4) · Condylomata Acuminata (3) · Penile Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Melanoma (2) · Neoplasms (2) · Vaginal Neoplasms (2) · Vulvar Neoplasms (2) · Acquired Immunodeficiency Syndrome (1) · Anal Canal Carcinoma (1)
Neoplasms (20) · Neoplasms by Site (20) · Urogenital Diseases (15) · Genital Diseases (14) · Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10) · Urogenital Neoplasms (10) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Genital Diseases, Female (8) · Genital Neoplasms, Female (8) · Head and Neck Neoplasms (8) · Uterine Cervical Diseases (8) · Uterine Diseases (8) · Uterine Neoplasms (8)
pembrolizumab (3) · Adoptive Transfer (2) · Blood Specimen Collection (2) · Drug Therapy (2) · Radiotherapy (2) · aldesleukin (2) · Carboplatin (1) · Chemoradiotherapy (1) · Cisplatin (1) · Clinical Trials, Phase II as Topic (1) · Colposcopy (1) · Costs and Cost Analysis (1) · Cytological Techniques (1) · Human Papillomavirus DNA Tests (1) · Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (1)
Shanghai Bovax Biotechnology Co., Ltd. (3) · Christian Hinrichs (2) · Memorial Sloan Kettering Cancer Center (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · Assuntina G. Sacco, MD (1) · Boston Medical Center (1) · Cue Biopharma (1) · European Institute of Oncology (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · ImmunityBio, Inc. (1) · Institut Bergonié (1) · Instituto do Cancer do Estado de São Paulo (1) · Jennifer Dorth (1) · Kenya Medical Research Institute (1) · Meharry Medical College (1)
United States (19) · China (5) · France (2) · Brazil (1) · Denmark (1) · Italy (1) · Poland (1) · Rwanda (1) · Spain (1)
Christian S Hinrichs, MD (2) · Acharf Shamseddine, MD (1) · Anna Giuliano, PhD (1) · Antonio Amelio, PhD (1) · Bobby Reddy, MD (1) · Carole Fakhry, MD, MPH (1) · Christina Son, MD (1) · Daniela Alterio (1) · David Spriggs, MD (1) · Dawn Pinchasik, MD (1) · Ezra Cohen, MD (1) · Guohua Li (1) · Jennifer Dorth, MD, MHSc (1) · Lidong Gao, Master (1)
PMID 11071210, PMID 17405118, PMID 17499406, PMID 25232064, PMID 25483700, PMID 27406936, PMID 28238631, PMID 28821519, PMID 29361344, PMID 29417310, PMID 29424778, PMID 30297124, PMID 30927547, PMID 31402238, PMID 31964784, PMID 34965951, PMID 34998048, PMID 36008069, PMID 36353194, PMID 37207682, PMID 37410084, PMID 37506588, PMID 37585432, PMID 40204996, PMID 40579407, PMID 41296233, PMID 41653072
2016 (1), U01CA287904 (1), U54CA254568 (1)